Morning Edition
Weekdays 4 - 9 a.m.
NPR's award-winning newsmagazine, featuring in-depth reporting on today's news. The program provides analysis, context, background, and commentary on news, issues, business, technology, art and human interest stories. It's up-to-the-minute news that prepares listeners for the day ahead.
-
Israel has not claimed explicit responsibility for the attacks. NPR's Steve Inskeep talks to Aaron David Miller, former State Department negotiator, about what's the strategy behind the attacks.
-
Trump can now start selling his majority stake in the Truth Social parent company, as a lockup on insider sales expires. But that could tank the price of the stock.
-
In Lebanon, victims were buried after a cyberattack Tuesday that detonated thousands of hand-held pagers used by the militant group Hezbollah. The next day there was a second wave of attacks.
-
The explosions in Lebanon are the latest in a series of lethal attacks attributed to Israel, and carried out against its leading enemies in their heavily guarded capitals.
-
Labor unions have been active in the presidential campaign this cycle, but the Teamsters -- a large, prominent union -- says it won't endorse either Donald Trump or Kamala Harris. Why?
-
The highest-earning YouTuber, MrBeast, is facing a lawsuit after contestants on his Amazon reality show claimed he mistreated them. NPR's Steve Inskeep speaks with "Variety" reporter Todd Spangler.
-
A new study finds more than 3,000 chemicals used in food packaging are getting into people's bodies. Some — including BPA, phthalates and PFAS — have clear health concerns; others are unstudied.
-
Is the U.S. banning TikTok essentially censorship? NPR's Leila Fadel speaks with an attorney whose firm filed a petition on behalf of a TikTok creator seeking to stop the U.S. ban.
-
Former President Jimmy Carter receives one more award -- this time for his writing. NPR's Steve Inskeep talks to his grandson Jason Carter.
-
It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease. So far, only a few patients have received the long-awaited treatments.